Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies-Reference-Cited by-同舟云学术

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies

Published:2021-08-09 Issue:9 Volume:38 Page:4975-4985
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Giovannoni Gavin^ORCID,Comi Giancarlo^ORCID,Rammohan Kottil^ORCID,Rieckmann Peter,Dangond Fernando^ORCID,Keller Birgit^ORCID,Jack Dominic^ORCID,Vermersch Patrick^ORCID

Funder

Merck KGaA

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-021-01865-w.pdf

Reference24 articles.

1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622–36.

2. Capra R, Cordioli C, Rasia S, et al. Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. Mult Scler. 2017;23(13):1757–61.

3. Giovannoni G. Do we have equipoise when it comes to how we treat active multiple sclerosis? Lancet Neurol. 2019;18(10):909–11.